Overview of Climene

The medicinal product Climene is a prescription-only medication used for Hormone Replacement Therapy (HRT). It is a combination product designed to address symptoms arising from hormonal changes in menopausal women.

Quick Facts

Property	Description
Active ingredients	Estradiol valerate, Cyproterone acetate
Form	Coated tablets
Pharmacological class	Estrogen/Progestogen combination
General purpose	Alleviation of oestrogen deficiency symptoms
Origin	Synthetic steroidal derivatives

Climene: Defining the Therapeutic Class and Composition

Climene is categorized as an Estrogen/Progestogen combination, a major sub-class of HRT. The drug contains two distinct active ingredients: Estradiol valerate and Cyproterone acetate. Both components are synthetic steroidal derivatives formulated as coated tablets for oral administration in a sequential preparation. This specific formulation, utilizing Cyproterone acetate, is clinically recognized for providing effective protection to the uterine lining.

What is the Role of Estradiol Valerate and Cyproterone Acetate?

The primary components serve complementary roles. Estradiol valerate provides the necessary oestrogen action by compensating for the body’s natural decline in estradiol production. Conversely, Cyproterone acetate provides crucial progestogenic action, which is vital for protecting the uterine lining (endometrium) from potential overstimulation by unopposed estrogen. Furthermore, this component possesses a distinct antiandrogenic effect by blocking certain male hormones through androgen receptor antagonism. This dual functionality ensures a balanced hormonal profile and represents a key differentiating factor in this combination HRT therapy.

General Purpose: Treating Symptoms of Oestrogen Deficiency

The overall general purpose of Climene is to restore hormonal balance to menopausal women experiencing the discomforts of the climacteric syndrome. The therapy aims to mitigate the various systemic physical and emotional complaints associated with the underlying oestrogen deficiency symptoms. For example, it is typically used to relieve common complaints like hot flashes and night sweats. Therapy of this type is intended to help ease generalized discomfort and promote hormonal stability during the menopausal transition.

Regulatory References

What side effects are possible with Climene?

Possible Side Effects and Safety Information

The safety profile for Climene, an estrogen/progestogen combination HRT, is established through comprehensive regulatory data, classifying possible health events by frequency and body system involvement.

Adverse Reaction Classification

The adverse reactions documented in official regulatory documents are classified by their expected rate of occurrence:

Common Reactions (ge 1/100 to < 1/10): These include headache, nausea, abdominal pain, and breast tenderness or pain. Changes in body weight and fluid retention (edema) are also commonly observed.
Uncommon Reactions (ge 1/1,000 to < 1/100): These may include migraine, dizziness, and mood disturbances, such as nervousness or depression.

Common side effects, particularly irregular bleeding or spotting and breast tenderness, may be more frequent during the first few months of treatment and often diminish with continued use.

Serious Safety Considerations

The official labeling documents rare but clinically significant risks associated with combination HRT:

System-Organ Class	Serious Adverse Reaction
Vascular Disorders	Venous Thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism; Arterial Thromboembolism (e.g., stroke, myocardial infarction).
Neoplasms	Increased risk of Breast Cancer and Ovarian Cancer; risk of Endometrial Hyperplasia/Carcinoma (mitigated by the progestogen component).
Hepatobiliary Disorders	Development of Hepatic Adenomas or carcinomas.

Safety Restrictions and Population Notes

The product is formally contraindicated in individuals with a current or past history of breast cancer, known or suspected oestrogen-dependent malignant tumours, or a history of VTE or arterial thromboembolic disease. For women with an intact uterus, the inclusion of the progestogen component is a mandatory safety feature to protect the endometrium. Furthermore, the risk of serious events, including VTE and stroke, is documented to increase with the duration of use of combination HRT. Close clinical surveillance, including blood pressure monitoring, is a standard requirement noted in the official prescribing information.

Overdose and Emergency Response

The regulatory documentation for Climene describes the potential manifestations and required emergency actions in the event of an overdose.

Acute overdose with the hormonal components in Climene (Estradiol valerate and Cyproterone acetate) is generally classified by regulatory agencies as not immediately life-threatening. Documented clinical manifestations of an acute, excessive intake often include gastrointestinal effects such as Nausea and Vomiting, along with other Gastric complaints. Additional formally listed signs are Breast Tension/Tenderness and Vaginal Bleeding, a manifestation consistent with withdrawal bleeding from high doses of hormonal substances.

Management is restricted to supportive care. Regulatory information confirms that no specific antidote is known for the effects of this hormonal combination, and treatment must therefore be entirely symptomatic.

Official Emergency Triggers:

Immediate medical attention is explicitly required if a patient experiences severe upper abdominal complaints, liver enlargement, or any signs of intra-abdominal haemorrhage. These are severe, rare events associated with hormonal substance use that necessitate immediate consultation for a differential diagnosis of a liver tumour, as mandated by official labeling.

Therapeutic Uses of Climene

What Climene Treats: Main Uses and Benefits

Climene is commonly used as a form of Hormone Replacement Therapy (HRT) to manage conditions characterized by systemic and localized discomfort due to oestrogen deficiency. This combination therapy is considered relevant for easing symptoms that interfere with daily functioning and create noticeable physiological strain. It is relevant for managing symptoms that interfere with daily comfort, including symptoms related to heightened physiological activity (like hot flashes and night sweats), psycho-emotional complaints (such as mood instability and irritability), and symptoms of urogenital atrophy (including vaginal dryness and dyspareunia).

This regimen is primarily relevant in clinical settings that involve chronic or episodic symptom patterns and is also applied in specific scenarios, such as for the prevention of postmenopausal osteoporosis in women at high fracture risk who cannot use other treatments. It is considered relevant for menopausal women with an intact uterus and is applied in contexts where additional support for symptom management is needed in the presence of the uterine lining.

“The therapy assists with maintaining functional stability in contexts where symptoms create noticeable physiological strain, supporting patients during episodes of heightened discomfort.”

Quick Fact: Therapeutic Focus: Symptom Domains

Symptom Domain	General Benefit Provided
Systemic Vasomotor	Contributes to easing the overall symptom load
Urogenital Atrophy	Supports patients during episodes of heightened discomfort
Bone Health (Long-term)	Provides supportive relief when symptoms interfere with routine activities

Eligibility and Restrictions for Use

Who Can and Cannot Use Climene?

Climene is an officially documented treatment for postmenopausal women with an intact uterus who are experiencing symptoms of oestrogen deficiency. The medicine is not indicated for use in the pediatric population (children and adolescents).

Absolute Contraindications

Climene is contraindicated and must not be used by individuals who have or have had specific conditions, as stated in regulatory labeling:

Oestrogen-dependent malignant tumours, including breast cancer, or any suspicion of these conditions.
A current or history of venous thromboembolism (VTE), arterial thromboembolic disease (e.g., heart attack or stroke), or known thrombophilic disorders.
Severe liver disease where liver function has not returned to normal, or current/history of liver tumours.
The presence of a meningioma or a history of one.
Pregnancy (known or suspected) or breastfeeding.

Condition-Based Restrictions

Use of Climene requires strict medical supervision for patients with conditions such as diabetes, hypertension, or uterine fibroids. Use is also contraindicated in individuals with severe hypertriglyceridaemia or porphyria.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Climene’s official interaction profile, based on regulatory labeling, is structured around substances that affect the systemic levels of its active steroid components, Estradiol valerate and Cyproterone acetate.

Documented Pharmacokinetic Interactions

Co-administration with certain medicinal products is documented to alter the body's processing of Climene. These interactions are primarily categorized by how they affect drug clearance:

Mechanism of Interaction	Interacting Substances/Classes
Enzyme Induction	Barbiturates, Rifampicin, Carbamazepine, Phenytoin, Rifabutin, Phenylbutazone, Primidone, and herbal remedies (e.g., St. John's Wort)
Intestinal Flora Alteration	Certain broad-spectrum antibiotics (e.g., Ampicillin)

Enzyme-inducing agents are officially cited for accelerating the metabolism of the steroid hormones, while certain antibiotics are documented to reduce active substance levels by altering the intestinal flora. Both mechanisms may lead to a reduction in the exposure of Climene's components.

Specific Regulatory Restrictions

An essential, component-specific restriction exists: Meningioma (previous or current) requires the permanent discontinuation of Climene treatment. This restriction is linked to the Cyproterone acetate component.

Other Official Constraints

Climene is documented to interfere with the results of specific laboratory tests, including coagulation parameters and endocrine function tests, which must be considered when interpreting diagnostic results. The regulatory documents also note that the product has not been expressly examined in patients with impaired kidney function.

Mechanism of Action

Climene is a product containing a combination of estradiol valerate and cyproterone acetate. Its pharmacodynamic action involves two distinct mechanisms mediated by its active components.

The estradiol valerate component is a synthetic precursor to 17beta-estradiol, which functions as an agonist at the estrogen receptors (ERalpha and ERbeta). Upon cellular uptake, the activated estrogen receptor complex translocates to the nucleus where it binds to specific Estrogen Response Elements (EREs) on the DNA. This interaction modulates the transcription of target genes. The subsequent cascade alters the systemic regulation of gonadotropin secretion from the pituitary gland, specifically reducing the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

The cyproterone acetate component acts as a progestogen agonist at the progesterone receptors (PR) and a competitive antagonist at the androgen receptors (AR). Agonism at the PR contributes to the overall suppression of pituitary gonadotropin release, reinforcing the estrogenic effect. Antagonism at the AR blocks the binding of endogenous androgens (like testosterone) at receptor sites in various target tissues, thereby inhibiting androgen-mediated intracellular signaling pathways and associated transcriptional activity.

Dosage and Administration Information

How to Use Climene: Official Administration Guidelines

Climene is an oral, sequential hormonal preparation. Adherence to the prescribed regimen and timing is essential for proper use.

Administration Scope

Parameter	Instruction
Route of Administration	The tablets are for oral use and must be swallowed whole with some liquid.
Dosing Schedule	One tablet is taken daily. The sequence involves a specific number of hormone-only tablets followed by combined tablets and a tablet-free interval or non-hormonal tablets, completing a 28-day cycle.
Timing in Relation to Meals	Tablets should be taken at about the same time each day, regardless of whether they are taken with food.

Procedural and Timing Rules

Start Time Rule	Instruction
Menstruating Patients	Start the first tablet on Day 5 of the cycle (Day 1 is the first day of menstruation).
Postmenopausal or Amenorrhoeic Patients	May start the first tablet on any day after pregnancy has been ruled out.

Missed-Dose Instructions

If a tablet is not taken at the usual time, it must be taken within 12 hours of that time to minimize the potential for intermenstrual bleeding.
If more than 12 hours have passed since the scheduled time, that tablet should be skipped, and the patient should resume taking the next tablet at the usual time.

Cycle Continuation

After finishing the entire pack, the next pack of Climene is started on the following day without any further delay, continuing the cyclic use. If no withdrawal bleeding occurs during the tablet-free interval, a new pack should not be started until pregnancy has been ruled out.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Climene

Evidence for Symptom Management of Oestrogen Deficiency

Research has consistently been applied in studies examining patient-reported outcomes related to the climacteric syndrome, which is characterized by fluctuating or episodic manifestations. The primary study type was evaluated in short-term Randomized Controlled Trials (RCTs) and various observational settings. These studies focused on postmenopausal women experiencing discomforts like hot flashes, night sweats, and changes in mood. Research examined specific scores that measure the intensity and frequency of vasomotor symptoms and patient-reported outcomes describing perceived discomfort.

Findings describe patterns observed in the studies related to changes in these systemic and functional imbalances. Studies report how symptoms evolved in the observed populations over defined time intervals, often showing short-term changes in both physical discomfort and psycho-emotional complaints. This evidence contributes to the broader evidence landscape regarding how combined hormone therapy was studied for conditions involving periods of heightened symptoms.

Evidence for Prevention of Postmenopausal Osteoporosis

Research examined the use of this combined therapy in the context of preventing bone mass loss in postmenopausal women at high risk for fracture. Studies was evaluated in both medium-term RCTs (lasting around two years) and longer-term observational data that monitored physiological strain. The main outcomes studies explored were changes in Bone Mineral Density (BMD), usually measured at the hip and spine, and shifts in the biochemical markers of bone turnover.

Research monitored BMD metrics, focusing on whether stability or increases in bone density was observed in some studies over defined intervals. Regulatory guidelines restrict the use of any hormone therapy for this purpose to women who can not use other specialized bone health treatments, which reflects the regulatory rationale based on the overall evidence profile for this therapeutic class.

What Remains Uncertain and Areas for Future Research

The overall research landscape has provided context but not individual predictions. Key limitations in the evidence base include the short duration of many of the controlled trials, meaning the full profile of long-term change is less known. Comparative evidence is lacking for many direct comparisons against all alternative HRT formulations currently on the market.

Furthermore, evidence quality varies across studies, and findings related to complex outcomes like overall cardiovascular risk are generally extrapolated from large, diverse studies of the HRT class rather than being dedicated to this specific formulation. The evidence highlights what is known—and what is still uncertain. Research is ongoing to provide more comprehensive data.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Climene (FAQ)

Q: What is the purpose of the lighter-colored tablets in the Climene pack?

Climene is a sequential combined therapy. According to the official product information, the lighter-colored (pink) tablets contain both estradiol valerate (estrogen) and cyproterone acetate (progestogen). This combination is taken after the estrogen-only tablets to ensure the uterine lining is protected during the cycle.

Q: Does Climene affect emotional symptoms like mood swings?

The official safety profile for HRT preparations includes reports of mood alterations. These mood swings or feelings of a depressive mood are documented as potential uncommon undesirable effects. It is important to remember that these are general findings and not individualized predictions.

Q: Will Climene affect my blood pressure?

Official regulatory documents recommend that blood pressure be monitored regularly during treatment with Climene. Although an increase in blood pressure is documented as a rare undesirable effect, discontinuation of treatment is warranted if a medically significant rise in blood pressure occurs.

Q: Will I stop having withdrawal bleeding completely over time with Climene?

For some women using sequential combined HRT, regulatory documents indicate that the predictable withdrawal bleeding may become increasingly absent over time. However, if any bleeding outside of the expected withdrawal time is frequent, persistent, or recurrent, it should be discussed with a healthcare professional for investigation.

Q: Is it safe to use Climene for more than 5 years?

Official guidelines state that Hormone Replacement Therapy (HRT) should be limited to the shortest duration necessary to achieve the treatment goal. The benefit and risk profile should be carefully re-evaluated at least once per year by a healthcare provider. This ensures that the therapy is only continued as long as the benefits clearly outweigh the potential risks associated with prolonged use.

Q: What is Climene's effect on my cholesterol and lipid profile?

Regulatory information indicates that systemic HRT may influence lipid metabolism and glucose tolerance. Patients who have very high levels of triglycerides (hypertriglyceridemia) need close monitoring, as oral estrogen therapy has been rarely linked to extreme increases in triglycerides that may cause pancreatitis.

Q: Does Climene interact with my diabetes medicines?

Official product information notes that Hormone Replacement Therapy can potentially affect the body's glucose tolerance. For women with diabetes, this means that the dosage of any existing antidiabetic treatment may require adjustment. Clinical monitoring may be necessary when Climene is used by patients with diabetes.

Q: Can I use Climene if I've had a hysterectomy?

Climene is a combined preparation, containing both estrogen and progestogen, and is indicated for women who have an intact uterus. For women who do not have a uterus (post-hysterectomy), official guidance notes that an estrogen-only preparation is generally used for patients without a uterus.

Q: Is Climene used for perimenopause symptoms?

According to official regulatory labeling, Climene is indicated for treating estrogen deficiency symptoms in postmenopausal women. Climene's indication is limited to postmenopausal women experiencing estrogen deficiency symptoms.

Q: How does age and time since menopause affect the risk profile for Climene?

Official safety data shows that the risk for serious conditions like stroke and venous thromboembolism (VTE) is higher for women who start HRT later in life or many years after menopause. Due to this factor, treatment should be initiated using the lowest effective dose for the shortest period necessary.

Q: What should I do about breakthrough spotting after the adjustment period (first 6 months)?

While breakthrough bleeding or spotting is common during the first few months as the body adjusts, official warnings apply to bleeding that continues afterward. If the bleeding is frequent, persistent, or recurrent after approximately 6 months of treatment, official labeling indicates that the cause should be investigated by a doctor.

Q: Does Climene cause thinning or thickening of hair?

Official regulatory documents mention that alopecia (hair loss) and hirsutism (excessive body hair growth) have been reported as uncommon undesirable effects with similar types of HRT. These effects are not experienced by most users, but are noted in the safety profile.

Q: What is sequential combined therapy for HRT?

Sequential combined therapy is a type of HRT where estrogen is taken continuously, and a progestogen is added for a specific period during the cycle. The method aims to provide estrogen replacement while including progestogen for the protection of the uterine lining (endometrium). The sequence of hormones typically leads to a predictable, regular withdrawal bleeding similar to a monthly period.

Q: Is Climene safe for women over 65?

Official guidelines note that for women over 65 years of age, the absolute risk of serious side effects like stroke and VTE (blood clots) increases. Therefore, the overall balance of benefits and risks should be discussed with a healthcare professional. The general guidance is to use the lowest effective dose for the shortest necessary duration.

Q: Does Climene help with sleep quality?

Climene is indicated to treat symptoms of estrogen deficiency, which can include sleep disturbances linked to night sweats and hot flashes. However, the official safety documentation also lists insomnia (difficulty sleeping) as a potential undesirable effect for some users of this type of therapy.

Q: Can Climene change my sex drive or libido?

Official safety profiles for this type of HRT report that changes in libido (sex drive) have been documented as an uncommon or rare undesirable effect. This means that both a decrease and an increase in sex drive have been reported in some users.

Q: Does Climene affect mammogram results or breast screening?

Official documents state that Hormone Replacement Therapy may increase mammographic density of the breast tissue. This change can potentially complicate the radiological detection of breast cancer during routine screening. Breast assessment is a routine procedure performed by a healthcare professional before starting and periodically during treatment.

Q: Can Climene cause gallbladder problems?

Official regulatory warnings note that taking estrogen-containing HRT is known to increase the risk of gallbladder disease in women who are postmenopausal.

Q: I am lactose intolerant, are there any inactive ingredients in Climene I should know about?

The official list of ingredients for Climene tablets confirms they contain the inactive ingredients lactose and sucrose (types of sugars). Patients with rare hereditary conditions such as galactose or fructose intolerance should discuss the use of this medicine with a healthcare provider.

How should Climene be stored and disposed of?

Official Storage Requirements

Climene Tablets must be stored in the original packs at a controlled room temperature to maintain product stability. The required storage conditions specify temperatures below 30°C, though some regional labeling mandates storage below 25°C. The medicine must be protected from both moisture and direct sunlight.

Child Safety and Disposal

It is an explicit regulatory requirement that Climene be kept out of the sight and reach of children.

Disposal of unused or expired tablets must be done according to local regulations. The preferred method is typically through a formal drug take-back program. If a take-back option is unavailable, the medicine should be mixed with an undesirable substance (such as dirt or used coffee grounds) in a sealed container before being placed in the household trash, and personal information on the packaging must be removed.

Climene